CAJ | 학술논문

目的：探讨生物梅里埃肠道细菌药敏试验试剂盒ATB G（-）5在临床应用中存在的缺陷，并提出补救（解决）方案。方法以《美国临床和实验室标准化协会（CLSI）M100-S23-表2A肠杆菌科细菌抑菌圈直径和最低抑菌浓度解释标准》（简称CLSI标准）提供的肠杆菌科细菌对应抗菌药物拐点作为标准，对生物梅里埃药敏试验试剂盒ATB G（-）5抗菌药物覆盖情况与各抗菌药物拐点质量浓度进行对比分析。结果试剂盒ATB G（-）5不包括CLSI标准推荐的氯霉素类、磷霉素及硝基呋喃类抗菌药物；试剂盒ATB G（-）5提供的19种抗菌药物拐点均与CLSI标准推荐的抗菌药物拐点不一致或不包含，从而可能导致临床药敏试验报告出现假敏感或假耐药情况。结论以现行CLSI标准作为参考标准，单独使用试剂盒ATB G（-）5进行肠杆菌科细菌药敏试验将产生较大误差，甚至错误，必须用其他药敏试验进行修正方可发出报告。
목적：탐토생물매리애장도세균약민시험시제합ATB G（-）5재림상응용중존재적결함，병제출보구（해결）방안。방법이《미국림상화실험실표준화협회（CLSI）M100-S23-표2A장간균과세균억균권직경화최저억균농도해석표준》（간칭CLSI표준）제공적장간균과세균대응항균약물괴점작위표준，대생물매리애약민시험시제합ATB G（-）5항균약물복개정황여각항균약물괴점질량농도진행대비분석。결과시제합ATB G（-）5불포괄CLSI표준추천적록매소류、린매소급초기부남류항균약물；시제합ATB G（-）5제공적19충항균약물괴점균여CLSI표준추천적항균약물괴점불일치혹불포함，종이가능도치림상약민시험보고출현가민감혹가내약정황。결론이현행CLSI표준작위삼고표준，단독사용시제합ATB G（-）5진행장간균과세균약민시험장산생교대오차，심지착오，필수용기타약민시험진행수정방가발출보고。
Objective To approach the limitations of bioMerieux enterobacteria susceptibility test kit ATB G (-)5 in clinical application and to propose remedies. Methods In line with break points of antibacterial agents of enterobacteriaceae provided by(abbreviated as CLSI)M100-S23 as the standard,the coverage condition of antibacterial agents of bioMerieux enter-obacteria susceptibility test kit ATB G(-)5 and their quality concentrations of break points were compared and analyzed. Results The kit ABT G(-)5 excluded three antibacterial agents as follows:chloromycetin,fosfomycin and nitrofurans recommend by CLSI;The break points of 19 antibacterial agents in the kit ATB G (-)5 were not inconsistent or did not contain with those recommended by CLSI M100-S23,which may lead to error drug sensitivity tests,false sensitive or false drug resistance. Conclusion Under the current CLSI reference standards,the sole application of kit ATB G(-)5 forenterobacteriaceae bacteria susceptibility test may came out larger errors or mistakes. Besides,the results must be corrected by other necessary susceptibility tests before the report is issued.